Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.

Shaman AM, Bain SC, Bakris GL, Buse JB, Idorn T, Mahaffey KW, Mann JFE, Nauck MA, Rasmussen S, Rossing P, Wolthers B, Zinman B, Perkovic V

Circulation14 Dec 2021Cited by 209 (Europe PMC)

PMID34903039PMCIDPMC8860212DOI10.1161/circulationaha.121.055459PepBankPUB-34903039

Download PDF PubMedAsk about this study

Jump to 18 results

Summary

BackgroundWe assessed the effect of once-weekly semaglutide and once-daily liraglutide on kidney outcomes in type 2 diabetes.MethodsPooled (n=12 637) and by-trial data from SUSTAIN 6 (Trial to Evaluate Cardiovascular and Other Long-Term Outcomes With Semaglutide in Subjects With Type 2 Diabetes; n=3297) and LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; n=9340) were assessed for albuminuria change, annual slope of estimated glomerular filtration rate (eGFR) change, and time to persistent eGFR reduction (30%, 40%, 50%, and 57%) from baseline.ResultsThe median follow-up durations were 2.1 years for SUSTAIN 6 and 3.8 years for LEADER. In the pooled analysis, semaglutide/liraglutide lowered albuminuria from baseline to 2 years after randomization by 24% versus placebo (95% CI, 20%-27%; P<0.001). Significant reductions were also observed in by-trial data analyses (P<0.001 for all), the largest being with semaglutide 1.0 mg (33% [95% CI, 24%-40%]; P<0.001) at 2 years. With semaglutide 1.0 mg and liraglutide, eGFR slope decline was significantly slowed by 0.87 and 0.26 mL/min/1.73 m²/y (PP<0.001), respectively, versus placebo. Effects appeared larger in patients with baseline eGFR 2 (P_interaction=0.06 and 0.008 for semaglutide 1.0 mg and liraglutide, respectively). Semaglutide/liraglutide significantly lowered risk of persistent 40% and 50% eGFR reductions versus placebo (hazard ratio [HR], 0.86 [95% CI, 0.75-0.99]; P=0.039 and HR, 0.80 [95% CI, 0.66-0.97]; P=0.023, respectively). Similar, nonsignificant, directional results were observed for 30% and 57% eGFR reductions (HR, 0.92 [95% CI, 0.84-1.02]; P=0.10 and HR, 0.89 [95% CI, 0.69-1.13]; P=0.34). In patients with baseline eGFR 30 to 2, the likelihood of persistent reduction for all thresholds was increased, ranging from HR 0.71 for 30% reduction (95% CI, 0.59-0.85; P=0.0003, P_interaction=0.017) to 0.54 for 57% reduction (95% CI, 0.36-0.81; P=0.003, P_interaction=0.035).ConclusionsIn patients with type 2 diabetes, semaglutide/liraglutide offered kidney-protective effects, which appeared more pronounced in patients with preexisting chronic kidney disease.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study18

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in SUSTAIN 6, semaglutide 1.0 mg lowered albuminuria by 33% versus placebo at 2 years, the largest reduction among the by-trial analyses.
In plain wordsIn adults with type 2 diabetes, semaglutide 1.0 mg lowered albumin in urine by 33% compared with placebo after 2 years.
Peptide
Semaglutide
Outcome
DecreaseAlbuminuria reduction at 2 years, semaglutide 1.0 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
1.0 mg · 2 yearsAs given in this study (human).
Measurements
Albuminuria reduction
33%
semaglutide 1.0 mg at 2 years
95% CI
24 to 40%
semaglutide 1.0 mg
Source sentences
Summary
the largest being with semaglutide 1.0 mg (33% [95% CI, 24%-40%]; P<0.001) at 2 years.
1 context sentence(design, population, supporting numbers)
Summary · context
The median follow-up durations were 2.1 years for SUSTAIN 6 and 3.8 years for LEADER.
Show in the study text Report a problemFND-3490303903
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in LEADER, liraglutide significantly reduced albuminuria versus placebo.
In plain wordsIn adults with type 2 diabetes, liraglutide lowered albumin in urine compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseAlbuminuria reduction, liraglutide (LEADER)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
Significant reductions were also observed in by-trial data analyses (P<0.001 for all)
2 context sentences(design, population, supporting numbers)
Summary · context
LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; n=9340)
Summary · context
The median follow-up durations were 2.1 years for SUSTAIN 6 and 3.8 years for LEADER.
Show in the study text Report a problemFND-3490303904
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, semaglutide 1.0 mg slowed the annual decline in eGFR by 0.87 mL/min/1.73 m² versus placebo.
In plain wordsIn adults with type 2 diabetes, semaglutide 1.0 mg slowed the yearly fall in kidney filtration compared with placebo.
Peptide
Semaglutide
Outcome
DecreaseeGFR slope decline, semaglutide 1.0 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
1.0 mg · median follow-up 2.1 yearsAs given in this study (human).
Measurements
eGFR slope decline slowed
0.87 mL/min/1.73 m²/y
semaglutide 1.0 mg versus placebo
Source sentences
Summary
With semaglutide 1.0 mg and liraglutide, eGFR slope decline was significantly slowed by 0.87 and 0.26 mL/min/1.73 m²/y (PP<0.001), respectively, versus placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
The median follow-up durations were 2.1 years for SUSTAIN 6 and 3.8 years for LEADER.
Show in the study text Report a problemFND-3490303905
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide slowed the annual decline in eGFR by 0.26 mL/min/1.73 m² versus placebo.
In plain wordsIn adults with type 2 diabetes, liraglutide slowed the yearly fall in kidney filtration compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseeGFR slope decline, liraglutide
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · median follow-up 3.8 yearsAs given in this study (human).
Measurements
eGFR slope decline slowed
0.26 mL/min/1.73 m²/y
liraglutide versus placebo
Source sentences
Summary
With semaglutide 1.0 mg and liraglutide, eGFR slope decline was significantly slowed by 0.87 and 0.26 mL/min/1.73 m²/y (PP<0.001), respectively, versus placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
The median follow-up durations were 2.1 years for SUSTAIN 6 and 3.8 years for LEADER.
Show in the study text Report a problemFND-3490303906
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, kidney effects of semaglutide 1.0 mg appeared larger with baseline eGFR below 60 than at or above 60 (P interaction = 0.06).
In plain wordsIn adults with type 2 diabetes, kidney effects of semaglutide 1.0 mg seemed larger in people with lower kidney function at the start.
Peptide
Semaglutide
Outcome
Not applicableEffect modification by baseline eGFR, semaglutide 1.0 mg
Study
n: not reported in source
Comparator
Baseline eGFR <60 versus ≥60
Outcome group
Kidney function · Kidney and urinary
Studied dose
1.0 mgAs given in this study (human).
Measurements
P interaction
0.06
semaglutide 1.0 mg
Source sentences
Summary
Effects appeared larger in patients with baseline eGFR 2 (P_interaction=0.06 and 0.008 for semaglutide 1.0 mg and liraglutide, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
The median follow-up durations were 2.1 years for SUSTAIN 6 and 3.8 years for LEADER.
Show in the study text Report a problemFND-3490303907
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, kidney effects of liraglutide appeared larger with baseline eGFR below 60 than at or above 60 (P interaction = 0.008).
In plain wordsIn adults with type 2 diabetes, kidney effects of liraglutide seemed larger in people with lower kidney function at the start.
Peptide
Liraglutide
Outcome
Not applicableEffect modification by baseline eGFR, liraglutide
Study
n: not reported in source
Comparator
Baseline eGFR <60 versus ≥60
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Measurements
P interaction
0.008
liraglutide
Source sentences
Summary
Effects appeared larger in patients with baseline eGFR 2 (P_interaction=0.06 and 0.008 for semaglutide 1.0 mg and liraglutide, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
The median follow-up durations were 2.1 years for SUSTAIN 6 and 3.8 years for LEADER.
Show in the study text Report a problemFND-3490303908

Studies that did not test the peptide alone12

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

07HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, pooled semaglutide and liraglutide lowered albuminuria by 24% versus placebo at 2 years.
In plain wordsIn adults with type 2 diabetes, semaglutide and liraglutide pooled together lowered albumin in urine by 24% compared with placebo.
Peptide
Semaglutide
Outcome
DecreaseAlbuminuria change at 2 years, pooled
Study
n = 12,637
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Measurements
Albuminuria reduction
24%
pooled semaglutide/liraglutide versus placebo
95% CI
20 to 27%
albuminuria reduction
Source sentences
Summary
In the pooled analysis, semaglutide/liraglutide lowered albuminuria from baseline to 2 years after randomization by 24% versus placebo (95% CI, 20%-27%; P<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
The median follow-up durations were 2.1 years for SUSTAIN 6 and 3.8 years for LEADER.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-3490303901
08HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, pooled semaglutide and liraglutide lowered albuminuria by 24% versus placebo at 2 years.
In plain wordsIn adults with type 2 diabetes, semaglutide and liraglutide pooled together lowered albumin in urine by 24% compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseAlbuminuria change at 2 years, pooled
Study
n = 12,637
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Measurements
Albuminuria reduction
24%
pooled semaglutide/liraglutide versus placebo
95% CI
20 to 27%
albuminuria reduction
Source sentences
Summary
In the pooled analysis, semaglutide/liraglutide lowered albuminuria from baseline to 2 years after randomization by 24% versus placebo (95% CI, 20%-27%; P<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
The median follow-up durations were 2.1 years for SUSTAIN 6 and 3.8 years for LEADER.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3490303902
09HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, pooled semaglutide and liraglutide lowered the risk of persistent 40% eGFR reduction versus placebo (HR 0.86).
In plain wordsIn adults with type 2 diabetes, semaglutide and liraglutide pooled together lowered the risk of a lasting 40% fall in kidney filtration.
Peptide
Semaglutide
Outcome
DecreasePersistent 40% eGFR reduction, pooled
Study
n = 12,637
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Measurements
HR
0.86 ratio
persistent 40% eGFR reduction, pooled
95% CI
0.75 to 0.99 ratio
40% eGFR reduction
Source sentences
Summary
Semaglutide/liraglutide significantly lowered risk of persistent 40% and 50% eGFR reductions versus placebo (hazard ratio [HR], 0.86 [95% CI, 0.75-0.99]; P=0.039 and HR, 0.80 [95% CI, 0.66-0.97]; P=0.023, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
The median follow-up durations were 2.1 years for SUSTAIN 6 and 3.8 years for LEADER.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-3490303909
10HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, pooled semaglutide and liraglutide lowered the risk of persistent 40% eGFR reduction versus placebo (HR 0.86).
In plain wordsIn adults with type 2 diabetes, semaglutide and liraglutide pooled together lowered the risk of a lasting 40% fall in kidney filtration.
Peptide
Liraglutide
Outcome
DecreasePersistent 40% eGFR reduction, pooled
Study
n = 12,637
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Measurements
HR
0.86 ratio
persistent 40% eGFR reduction, pooled
95% CI
0.75 to 0.99 ratio
40% eGFR reduction
Source sentences
Summary
Semaglutide/liraglutide significantly lowered risk of persistent 40% and 50% eGFR reductions versus placebo (hazard ratio [HR], 0.86 [95% CI, 0.75-0.99]; P=0.039 and HR, 0.80 [95% CI, 0.66-0.97]; P=0.023, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
The median follow-up durations were 2.1 years for SUSTAIN 6 and 3.8 years for LEADER.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3490303910
11HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, pooled semaglutide and liraglutide lowered the risk of persistent 50% eGFR reduction versus placebo (HR 0.80).
In plain wordsIn adults with type 2 diabetes, semaglutide and liraglutide pooled together lowered the risk of a lasting 50% fall in kidney filtration.
Peptide
Semaglutide
Outcome
DecreasePersistent 50% eGFR reduction, pooled
Study
n = 12,637
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Measurements
HR
0.8 ratio
persistent 50% eGFR reduction, pooled
95% CI
0.66 to 0.97 ratio
50% eGFR reduction
Source sentences
Summary
Semaglutide/liraglutide significantly lowered risk of persistent 40% and 50% eGFR reductions versus placebo (hazard ratio [HR], 0.86 [95% CI, 0.75-0.99]; P=0.039 and HR, 0.80 [95% CI, 0.66-0.97]; P=0.023, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
The median follow-up durations were 2.1 years for SUSTAIN 6 and 3.8 years for LEADER.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-3490303911
12HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, pooled semaglutide and liraglutide lowered the risk of persistent 50% eGFR reduction versus placebo (HR 0.80).
In plain wordsIn adults with type 2 diabetes, semaglutide and liraglutide pooled together lowered the risk of a lasting 50% fall in kidney filtration.
Peptide
Liraglutide
Outcome
DecreasePersistent 50% eGFR reduction, pooled
Study
n = 12,637
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Measurements
HR
0.8 ratio
persistent 50% eGFR reduction, pooled
95% CI
0.66 to 0.97 ratio
50% eGFR reduction
Source sentences
Summary
Semaglutide/liraglutide significantly lowered risk of persistent 40% and 50% eGFR reductions versus placebo (hazard ratio [HR], 0.86 [95% CI, 0.75-0.99]; P=0.039 and HR, 0.80 [95% CI, 0.66-0.97]; P=0.023, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
The median follow-up durations were 2.1 years for SUSTAIN 6 and 3.8 years for LEADER.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3490303912
13HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, pooled semaglutide and liraglutide showed a nonsignificant directional reduction in persistent 30% eGFR reduction versus placebo (HR 0.92).
In plain wordsIn adults with type 2 diabetes, semaglutide and liraglutide pooled together did not significantly lower the risk of a lasting 30% fall in kidney filtration.
Peptide
Semaglutide
Outcome
No significant changePersistent 30% eGFR reduction, pooled
Study
n = 12,637
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Measurements
HR
0.92 ratio
persistent 30% eGFR reduction, pooled
95% CI
0.84 to 1.02 ratio
30% eGFR reduction
Source sentences
Summary
Similar, nonsignificant, directional results were observed for 30% and 57% eGFR reductions (HR, 0.92 [95% CI, 0.84-1.02]; P=0.10 and HR, 0.89 [95% CI, 0.69-1.13]; P=0.34).
1 context sentence(design, population, supporting numbers)
Summary · context
The median follow-up durations were 2.1 years for SUSTAIN 6 and 3.8 years for LEADER.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-3490303913
14HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, pooled semaglutide and liraglutide showed a nonsignificant directional reduction in persistent 30% eGFR reduction versus placebo (HR 0.92).
In plain wordsIn adults with type 2 diabetes, semaglutide and liraglutide pooled together did not significantly lower the risk of a lasting 30% fall in kidney filtration.
Peptide
Liraglutide
Outcome
No significant changePersistent 30% eGFR reduction, pooled
Study
n = 12,637
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Measurements
HR
0.92 ratio
persistent 30% eGFR reduction, pooled
95% CI
0.84 to 1.02 ratio
30% eGFR reduction
Source sentences
Summary
Similar, nonsignificant, directional results were observed for 30% and 57% eGFR reductions (HR, 0.92 [95% CI, 0.84-1.02]; P=0.10 and HR, 0.89 [95% CI, 0.69-1.13]; P=0.34).
1 context sentence(design, population, supporting numbers)
Summary · context
The median follow-up durations were 2.1 years for SUSTAIN 6 and 3.8 years for LEADER.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3490303914
15HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, pooled semaglutide and liraglutide showed a nonsignificant directional reduction in persistent 57% eGFR reduction versus placebo (HR 0.89).
In plain wordsIn adults with type 2 diabetes, semaglutide and liraglutide pooled together did not significantly lower the risk of a lasting 57% fall in kidney filtration.
Peptide
Semaglutide
Outcome
No significant changePersistent 57% eGFR reduction, pooled
Study
n = 12,637
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Measurements
HR
0.89 ratio
persistent 57% eGFR reduction, pooled
95% CI
0.69 to 1.13 ratio
57% eGFR reduction
Source sentences
Summary
Similar, nonsignificant, directional results were observed for 30% and 57% eGFR reductions (HR, 0.92 [95% CI, 0.84-1.02]; P=0.10 and HR, 0.89 [95% CI, 0.69-1.13]; P=0.34).
1 context sentence(design, population, supporting numbers)
Summary · context
The median follow-up durations were 2.1 years for SUSTAIN 6 and 3.8 years for LEADER.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-3490303915
16HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, pooled semaglutide and liraglutide showed a nonsignificant directional reduction in persistent 57% eGFR reduction versus placebo (HR 0.89).
In plain wordsIn adults with type 2 diabetes, semaglutide and liraglutide pooled together did not significantly lower the risk of a lasting 57% fall in kidney filtration.
Peptide
Liraglutide
Outcome
No significant changePersistent 57% eGFR reduction, pooled
Study
n = 12,637
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Measurements
HR
0.89 ratio
persistent 57% eGFR reduction, pooled
95% CI
0.69 to 1.13 ratio
57% eGFR reduction
Source sentences
Summary
Similar, nonsignificant, directional results were observed for 30% and 57% eGFR reductions (HR, 0.92 [95% CI, 0.84-1.02]; P=0.10 and HR, 0.89 [95% CI, 0.69-1.13]; P=0.34).
1 context sentence(design, population, supporting numbers)
Summary · context
The median follow-up durations were 2.1 years for SUSTAIN 6 and 3.8 years for LEADER.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3490303916
17HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and baseline eGFR 30 to <60, pooled semaglutide and liraglutide lowered the risk of persistent eGFR reduction at all thresholds (HR 0.71 for 30% to 0.54 for 57%).
In plain wordsIn adults with type 2 diabetes and reduced kidney function, semaglutide and liraglutide pooled together lowered the risk of lasting kidney filtration falls.
Peptide
Semaglutide
Outcome
DecreasePersistent eGFR reduction in baseline eGFR 30 to <60, pooled
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Measurements
HR
0.71 ratio
30% reduction
HR
0.54 ratio
57% reduction
Source sentences
Summary
In patients with baseline eGFR 30 to 2, the likelihood of persistent reduction for all thresholds was increased, ranging from HR 0.71 for 30% reduction (95% CI, 0.59-0.85; P=0.0003, P_interaction=0.017) to 0.54 for 57% reduction (95% CI, 0.36-0.81; P=0.003, P_interaction=0.035).
1 context sentence(design, population, supporting numbers)
Summary · context
The median follow-up durations were 2.1 years for SUSTAIN 6 and 3.8 years for LEADER.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-3490303917
18HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and baseline eGFR 30 to <60, pooled semaglutide and liraglutide lowered the risk of persistent eGFR reduction at all thresholds (HR 0.71 for 30% to 0.54 for 57%).
In plain wordsIn adults with type 2 diabetes and reduced kidney function, semaglutide and liraglutide pooled together lowered the risk of lasting kidney filtration falls.
Peptide
Liraglutide
Outcome
DecreasePersistent eGFR reduction in baseline eGFR 30 to <60, pooled
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Measurements
HR
0.71 ratio
30% reduction
HR
0.54 ratio
57% reduction
Source sentences
Summary
In patients with baseline eGFR 30 to 2, the likelihood of persistent reduction for all thresholds was increased, ranging from HR 0.71 for 30% reduction (95% CI, 0.59-0.85; P=0.0003, P_interaction=0.017) to 0.54 for 57% reduction (95% CI, 0.36-0.81; P=0.003, P_interaction=0.035).
1 context sentence(design, population, supporting numbers)
Summary · context
The median follow-up durations were 2.1 years for SUSTAIN 6 and 3.8 years for LEADER.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3490303918

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.